Probiotic Pediococcus pentosaceus Li05 Improves Cholestasis through the FXR-SHP and FXR-FGF15 Pathways
Nutrients · 22.11.2023 · 15 (23) · 4864
DOI: 10.3390/nu15234864 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, online erschienen am 22.11.2023. Verfasst von Shengyi Han und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical …. Hauptthemen laut MEDLINE: Cholestasis, Probiotics. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Zhejiang Provincial Natural Science Foundation, Shandong Provincial Laboratory Project.
Abstract (Originalsprache)
Primary sclerosing cholangitis (PSC), a rare chronic cholestatic liver disease, is characterized by intrahepatic or extrahepatic strictures accompanied by biliary fibrosis. So far, there are no effective therapies to slow down the progression of this disease. Farnesoid X receptors (FXRs) are ligand-activated transcription factors involved in the control of bile acid (BA) synthesis and enterohepatic circulation. Therefore, targeting FXRs holds promise as a potential approach for treating PSC. Pediococcus pentosaceus Li05 is a probiotic that was isolated from healthy volunteers and has previously been shown to have an anti-inflammatory effect in DSS-induced colitis. In this study, we established a 3,5-diethoxycarbonyl-1,4-Dihydrocollidine (DDC)-induced cholestasis mouse model and investigated the effects of Pediococcus pentosaceus Li05 on PSC. Our findings revealed that administration of Li05 significantly attenuated liver damage, hepatic inflammation, and fibrosis, as well as bile duct hyperplasia. Li05 activated the hepatic FXR-SHP and ileal FXR-FGF15 signaling pathways to decrease the expression of Cyp7a1. In addition, the Li05-modulated gut microbiota structure especially improved the abundance of 7α-dehydroxylation bacteria like Eubacterium. The intervention of Li05 also improved the intestinal barrier and reduced bacterial endotoxin translocation. Based on these findings, Li05 shows promise for future application as a therapeutic strategy for cholestasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Di…
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
- Jinan Microecological Biomedicine Shandong Laboratory, Jinan 250000, China.
ORCID-Profile: Mingfei Yao
Förderung
- National Key Research and Development Program of China
- Zhejiang Provincial Natural Science Foundation
- Shandong Provincial Laboratory Project
- Research Project of Jinan Micro-ecological Biomedicine Shandong Laboratory
Zitieren
APA
Han, S., Wang, K., Shen, J., Xia, H., Lu, Y., Zhuge, A., Li, S., Qiu, B., Zhang, S., Dong, X., Yao, M., & Li, L. (2023). Probiotic Pediococcus pentosaceus Li05 Improves Cholestasis through the FXR-SHP and FXR-FGF15 Pathways. Nutrients, 15(23), 4864. https://doi.org/10.3390/nu15234864
Vancouver
Han S, Wang K, Shen J, Xia H, Lu Y, Zhuge A, et al. Probiotic Pediococcus pentosaceus Li05 Improves Cholestasis through the FXR-SHP and FXR-FGF15 Pathways. Nutrients. 2023;15(23):4864. doi:10.3390/nu15234864
BibTeX
@article{Han2023,
author = {Han, Shengyi and Wang, Kaicen and Shen, Jian and Xia, He and Lu, Yanmeng and Zhuge, Aoxiang and Li, Shengjie and Qiu, Bo and Zhang, Shuobo and Dong, Xiangmin and Yao, Mingfei and Li, Lanjuan},
title = {Probiotic Pediococcus pentosaceus Li05 Improves Cholestasis through the FXR-SHP and FXR-FGF15 Pathways},
journal = {Nutrients},
year = {2023},
volume = {15},
number = {23},
pages = {4864},
doi = {10.3390/nu15234864}
}
EUVIMED